ANIP Stock Recent News

Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impact Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impact

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue Adds two commercial assets ILUVIEN ® and YUTIQ ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafter Expected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from accelerated growth of Purified Cortrophin ® Gel in ophthalmology Increased geographic diversification with Alimera's established ex-US footprint, including direct operations in Europe PRINCETON, N.J.

ANIP's potential royalty revenue from two upcoming drug applications could generate $415 million annually, not reflected in the current share price. ANI Pharmaceuticals' legal action against CG Oncology could result in royalties for Cretostimogene, potentially adding $125 million per year. The Company's female testosterone drug could generate royalties of $290 million per year, with potential for additional indications and international sales.

BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global Healthcare Conference in New York City as follows:

NEW YORK , May 20, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) on behalf of the company's shareholders. The investigation seeks to determine whether ANI Pharmaceuticals's directors breached their fiduciary duties in connection with recent corporate actions.

ANI (ANIP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex® Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2024 Earnings Conference Call May 10, 2024 8:30 AM ET Company Participants Lisa Wilson - In-Site Communications, Investor Relations Nikhil Lalwani - President and Chief Executive Officer Stephen Carey - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Gary Nachman - Raymond James Leszek Sulewski - Truist Securities Vamil Divan - Guggenheim Securities Oren Livnat - H.C. Wainwright Timothy Chiang - Capital One Operator Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc. First Quarter 2024 Earnings Results Call.

Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

ANI Pharmaceuticals (ANIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.